Halozyme Therapeutics Announces Pricing of $1.3 Billion Convertible Notes Offering

Details

announced the pricing of its offering of $650 million of convertible senior notes due 2031 and $650 million of convertible senior notes due 2032, totaling $1.3 billion. The notes are convertible into the company's common stock under specific conditions, and the company also granted an option to purchase additional notes. Halozyme intends to use the net proceeds for general corporate purposes, including note repurchases and potential acquisitions.

Items reported

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.